ArticleRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)2025
Vaccine protection against COVID-19-related mortality in patients with schizophrenia: a retrospective cohort study.
Article in Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research on comorbidity characteristics and patterns of hospitalized participants with schizophrenia in China.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveThis study analyzed the role of vaccination in preventing COVID-19-related mortality in patients with schizophrenia.
methodsThis retrospective cohort study analyzed data from the Influenza Epidemiological Surveillance Information System (Sistema de Informação da Vigilância Epidemiológica da Gripe [SIVEP-Gripe]) database, focusing on patients aged = 18 years with laboratory-confirmed COVID-19 between February 2020 and February 2023. The primary exposure was schizophrenia. The primary outcome of interest was the role of vaccines in preventing COVID-19-associated mortality. Statistical analysis included multiple binary logistic regressions to determine the impact of schizophrenia on mortality and to compare vaccine protection between cohorts.
resultsThe cohort included 2,131,089 patients, 3,516 (0.2%) of whom had schizophrenia. After adjusting for potential confounders, patients with schizophrenia presented a significantly higher risk of severe disease (OR = 1.59, 95%CI 1.39-1.81) and mortality (OR = 1.65, 95%CI 1.45-1.87). After the booster dose, protection against mortality was estimated at 67.7% (95%CI 66.5-68.7) in the non-schizophrenia cohort and 62.4% (95%CI 44.1-74.6) in the schizophrenia cohort. Mortality rate differences of approximately 20% and 10% were observed between boosted and non-vaccinated individuals among the schizophrenia and non-schizophrenia cohorts, respectively. Consequently, five patients (95%CI 4-8) with schizophrenia and 10 patients (95%CI 9-11) in the general population would need to receive a booster dose to prevent one fatality.
conclusionsOur results suggest that vaccination provided similar protection against COVID-19-related mortality in individuals with and without schizophrenia. However, the magnitude of the intervention effect was double for individuals with schizophrenia due to their higher baseline risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.